Abstracts tagged "medication"

Abstract Number: 11 • 2016 ACR/ARHP Annual Meeting
Drug Prescribing Trends in Adults with Rheumatoid Arthritis: A Population-Based Comparative Study from 2005-2014
Alex Zamora-Legoff¹, Cynthia S. Crowson², Eric L. Matteson³, Sara J. Achenbach⁴ and Elena Myasoedova³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: To examine drug prescribing trends for patients with rheumatoid arthritis (RA) over recent years and compare them to matched non-RA subjects. Methods: Retrospective prescription…
Abstract Number: 1218 • 2015 ACR/ARHP Annual Meeting
Higher Education Is Associated with a Better Rheumatoid Arthritis Outcome Concerning Pain and Function but Not Disease Activity: Results from Swedish Registers
Xia Jiang¹, Maria Sandberg², Saedis Saevarsdottir³, Lars Alfredsson⁴, Lars Klareskog⁵ and Camilla Bengtsson⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Unit of Cardiovascular Epidemiology, Institute of Enviornmental Medicine, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁶The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: To investigate the influence of education (achieving university/college degree (high) or not (low)) on the outcomes of early RA, in terms of disease activity,…
Abstract Number: 1556 • 2015 ACR/ARHP Annual Meeting
The Medication Information-Seeking Behaviors of Rheumatoid Arthritis Patients Who Are Prescribed a New DMARD
Delesha Carpenter¹, Lorie Geryk², Courtney Arrindell³, Beth Jonas⁴ and Susan J. Blalock⁵, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Asheville, NC, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Research Ct, UNC-Chapel Hill, Chapel Hill, NC, ⁵School of Pharmacy, UNC at Chapel Hill, Chapel Hill, NC
Background/Purpose: We present preliminary longitudinal data about the information-seeking behaviors and medication experiences of RA patients who are prescribed a new DMARD. Methods: We recruited…
Abstract Number: 2106 • 2015 ACR/ARHP Annual Meeting
Intensification to Triple Therapy Non-Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States from 2009 to 2014
Jeffrey A. Sparks¹, Alexis A. Krumme², Olga S. Matlin³, Gregory Brill², William H. Shrank³, Niteesh K. Choudhry² and Daniel H. Solomon^2,4, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³CVS Caremark, Woonsocket, RI, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Several trials suggest that triple therapy with non-biologic disease-modifying antirheumatic drugs (ttDMARD) has similar efficacy compared to biologic DMARDs (bDMARD) for patients with RA.…
Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting
Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women
Denise Boudreau¹, Onchee Yu¹, Akhila Balasubramanian², Jane Grafton¹, Heidi Wirtz³, Andreas Grauer³, D. Barry Crittenden³ and Delia Scholes¹, ¹Group Health Research Institute, Seattle, WA, ²Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…
Abstract Number: 2324 • 2015 ACR/ARHP Annual Meeting
Understanding the Importance of a Patient’s Role in the Management of RA: Results from a Patient-Based Survey
Ara Dikranian¹, James Galloway², Jörn Kekow³, Anna Maniccia⁴, Dean Spurden⁵, Eustratios Bananis⁶, Allan Gibofsky⁷ and for the RA NarRAtives advisory panel, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Academic Department of Rheumatology, King´s College London, London, United Kingdom, ³University of Magdeburg, Magdeburg, Germany, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Tadworth, United Kingdom, ⁶Pfizer Inc, Collegeville, PA, ⁷Weill Cornell Medical College and Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, debilitating condition for which there is no cure. The RA NarRAtive is a global initiative to identify patient…
Abstract Number: 2526 • 2015 ACR/ARHP Annual Meeting
Perinatal Patterns of Medication Use in Women with Rheumatoid Arthritis: A Population-Based Study
Mary A De Vera^1,2, Eric C. Sayre², Nicole Tsao^1,2 and J Antonio Avina-Zubieta^2,3, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Perinatal Patterns of Medication Use in Women with Rheumatoid Arthritis: A Population-based StudyBackground/Purpose: Although the incidence of RA peaks during the 4th and 5th decades…
Abstract Number: 2528 • 2015 ACR/ARHP Annual Meeting
Utilization of Immune-Suppressive Medications during Pregnancy Among Women with Inflammatory Arthritis and Other Autoimmune Diseases
Jie Zhang^1,2, Jeffrey R. Curtis³, Fenglong Xie⁴, Melissa L. Mannion⁵, James D. Lewis^6,7, Megan E. B. Clowse⁸, Kenneth G. Saag³, Steven Bethard⁹, Jospeh Biggio⁹, Gerald McGwin⁹ and Timothy Beukelman¹⁰, ¹Epidemilogy, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Medicine, University of Pennsylvania, Philadelphia, PA, ⁸Clinical Rheumatologist, Duke University Medical Center, Durham, NC, ⁹UAB, Birmingham, AL, ¹⁰Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To examine difference in the prevalence of immunosuppressive medication use during pregnancy by type of autoimmune disease and by insurance (Medicaid versus commercial) in…
Abstract Number: 2537 • 2015 ACR/ARHP Annual Meeting
Prescription Medication Use in Sweden Among Pregnant Women with Systemic Lupus Erythematosus and General Population Comparators
Kristin Palmsten¹, Julia F Simard^2,3, Christina D Chambers^1,4 and Elizabeth V Arkema⁵, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁵Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: There is limited information regarding medication use patterns among pregnant women with systemic lupus erythematosus (SLE). We aimed to characterize trends of medications used…
Abstract Number: 1451 • 2014 ACR/ARHP Annual Meeting
Use of Analgesics in Patients with Knee and/or Hip Osteoarthritis: Results from the Amsterdam Osteoarthritis Cohort
Joyce van Tunen¹, Marike van der Leeden^1,2, Martin van der Esch¹, Leo D. Roorda¹, Willem F. Lems^3,4 and Joost Dekker⁵, ¹Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²Rehabilitation Medicine/EMGO, VU University Medical Center, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose Use of analgesics is recommended by international guidelines to reduce pain complaints related to knee and/or hip osteoarthritis. Underuse of analgesics might be substantial…
Abstract Number: 263 • 2014 ACR/ARHP Annual Meeting
Nutraceutical Products and Pain or Non-Pain Medications Use in Patients with Knee Osteoarthritis
Mei Chung¹, John B. Wong², Shaoyu Chang³ and Chenchen Wang⁴, ¹Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, ²Medicine/Clinical Decision Making, Tufts Medical Center, Boston, MA, ³Tufts Medical Center, Boston, MA, ⁴Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Knee osteoarthritis (OA) causes substantial health burden and economic costs including medications and neutraceuticals for pain. The aim of this analysis was to describe…
Abstract Number: 1108 • 2013 ACR/ARHP Annual Meeting
Methylphenidate Improves Concentration, Energy and Mood In Fibromyalgia
Robert S. Katz¹, Hannah Bond² and Frank Leavitt³, ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Central nervous system stimulants such as methylphenidate appear to have short term benefits for naming speed and cognitive functioning in fibromyalgia (FMS). Methylphenidate quickly…
Abstract Number: 328 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Philip J. Mease¹, Emily Edson-Heredia², Katherine C. Saunders³, Catherine L. Shuler², Baojin Zhu², Monica Chaudhari⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Eli Lilly and Company, Indianapolis, IN, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: The use of biologic therapy in psoriatic arthritis (PsA) has altered the disease course and has been shown to reduce disease activity. Data comparing…
Abstract Number: 2679 • 2013 ACR/ARHP Annual Meeting
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication Use
Linda T. Hiraki¹, Candace H. Feldman², Mary Beth Son³, Jessica M. Franklin⁴, Michael A. Fischer⁴, Daniel H. Solomon⁵, Seoyoung C. Kim⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication UseBackground/Purpose: We investigated incidence rates…
Abstract Number: 2132 • 2013 ACR/ARHP Annual Meeting
Short-Run Transitions In Pain States: Reflections Of Multiple Outcome Clinical Measures of Inadequate Pain Relief among Patients With Knee Osteoarthiritis
Stephanie Taylor¹, Christopher Black², Paul M. Peloso³, Philip G. Conaghan⁴, Leah Stokes², Mart A.F.J. van de Laar⁵, François Rannou⁶, Nigel K. Arden⁷ and Panagiotis Mavros², ¹Global Health Outcomes, Merck & Co., Inc., Whitehouse Station, NJ, ²Global Health Outcomes, Merck, Whitehouse Station, NJ, ³Clinical Research, Merck Sharp & Dohme Corp., Rahway, NJ, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Rheumatology, University of Twente & Medisch Spectrum Twente, Enschede, Netherlands, ⁶Physical Medicine and Rehabilitation Service, Paris-Descartes University, Cochin Hospital, Paris, France, ⁷NDORMS; MRC Lifecourse Epidemiology Unit, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom
Background/Purpose: Despite the importance of pain management in osteoarthritis (OA), there has been limited evidence confirming the adequacy of measuring pain relief in clinical practice setting. The objective of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].